<DOC>
	<DOCNO>NCT02905201</DOCNO>
	<brief_summary>The primary purpose study determine rate compliance abiraterone acetate prednisone ( AA + P ) treatment Colombian Castration-resistant metastatic prostate cancer ( mCRPC ) participant experience adequate response treatment , real-world clinical setting .</brief_summary>
	<brief_title>A Prospective Compliance Registry Patients With Metastatic Castration Resistant Prostate Cancer ( mCRPC )</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma prostate without neuroendocrine differentiation small cell histology Distant metastatic disease document positive bone scan metastatic lesion computerize tomography ( CT ) magnetic resonance imaging ( MRI ) Prescribed currently ( enrollment ) treat abiraterone acetate prednisone ( AA + P ) treatment Castrationresistant metastatic prostate cancer ( mCRPC ) accord local product label Having receive minimum 1 cycle AA + P ( 4 week ) , maximum 4 consecutive cycle AA + P ( 16 week ) prior study enrollment Eastern Cooperative Oncology Group ( ECOG ) performance status grade 0 , 1 2 enrollment Participants receive terminated abiraterone acetate treatment prostate cancer ( PCa ) past Received investigational drug ( include investigational vaccine ) use invasive investigational medical device less equal ( &lt; = ) 30 day start study first data collection time point Presence condition , opinion treat physician , prohibit participant participate study obscures assessment abiraterone acetate treatment mCRPC Known brain metastasis Pathological find consistent small cell carcinoma prostate</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>